YESTAR HEALTH (02393) has announced its financial performance for 2025. Revenue from continuing operations amounted to approximately RMB 1.49 billion, representing a decrease of 38.17% compared to the previous year. The company recorded a net loss attributable to owners of RMB 75.03 million, a reversal from a profit in the prior year. The loss per share was 3.22 cents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.